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Abstract
Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of
advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular,
World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years
started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures
at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation
guidelines on reducing the proportion of children initiating cART with advanced disease.
Methods: We included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immun-
odeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central,
East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North
American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials
(IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive
mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of
2006 and 2010 WHO cART initiation guidelines.
Results: We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income coun-
tries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from
70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-
income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual
decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions
in 2006 (low-, lower middle- and upper middle-income countries) and 2010 (all countries).
Conclusions: By 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment
initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced
disease. However, considerable global inequity remains, in 2013, >40% of children in low- and middle-income countries started
cART with severe immunodeficiency compared to <20% in high-income countries.
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1 | INTRODUCTION
World Health Organization (WHO) guidelines on initiating
combination antiretroviral therapy (cART) in children have
expanded paediatric cART eligibility. The initial WHO
guidelines (2002, revised in 2006) established CD4 thresholds
for cART initiation across all paediatric age groups [1]. In
2010, immediate cART initiation regardless of immunological
or clinical thresholds was recommended for children aged
<2 years [2] and expanded in 2013 to all children <5 years
Panayidou K et al. Journal of the International AIDS Society 2018, 21:e25200
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25200/full | https://doi.org/10.1002/jia2.25200
1
[3] and in 2016 to all adults and children living with HIV [4].
These modifications were largely predicated by the rapid HIV
disease progression and high morbidity and mortality in
infants and children [5-7], together with evidence of lower
mortality (particularly in infants <3 months of age) [8] as well
as better growth, immunological and morbidity outcomes and
less chronic organ system disease associated with early cART
initiation [9-19]. An additional motivation for recommending
earlier cART in children was to address the lag in paediatric
cART coverage [20].
Serial monitoring of CD4 at cART initiation is important for
programme evaluation, indicating the extent to which guideline
changes are successfully implemented so that children initiate
cART before onset of advanced HIV disease. An analysis from
sub-Saharan Africa, Asia, North America and Latin America
from 2004 to 2010 demonstrated reductions in the propor-
tions of children initiating cART with severe immunodeficiency,
but even in 2010 the vast majority of children in low- and
middle-income countries continued to start cART late [21].
The ongoing high burden of advanced HIV disease was a key
motivation for the recent WHO 2017 guidelines on managing
advanced disease [22]. We analysed CD4 measures at cART
initiation from an international collaboration of treatment pro-
grammes in sub-Saharan Africa, Asia, Europe, Central and
South America, and North America from 1996 to 2013 in
order to assess changes in the proportion of children starting
cART with advanced HIV disease and the impact of WHO
treatment initiation guidelines on this proportion.
2 | METHODS
2.1 | Data sources
Data were collated from four major cohort research networks:
the International Epidemiology Databases to Evaluate AIDS
(IeDEA); the Collaboration of Observational HIV Epidemiologi-
cal Research Europe (COHERE); the Adolescent Master Proto-
col (AMP) study of the Pediatric HIV/AIDS Cohort Study
(PHACS) network; and the 219C Long-Term Follow-Up Study
of the International Maternal Pediatric Adolescent AIDS Clini-
cal Trials (IMPAACT) network. IeDEA is a global consortium
with regional centres that pool clinical and epidemiological data
on individuals living with HIV; regions collecting paediatric data
are Caribbean/Central and South America, Asia-Pacific, East
Africa, West Africa, Central Africa and Southern Africa [23].
COHERE is a collaboration of European HIV cohorts that con-
ducts epidemiological research on the prognosis of people liv-
ing with HIV across Europe [24]. IMPAACT 219C and PHACS
AMP are US-based prospective cohort studies designed to
evaluate the impact of HIV infection and cART on youth. New
enrolment in recent years is limited [25-27]. Pooling of data
and their use in collaborative analyses were approved by local
institutional review boards. For the present study, regional cen-
tres sent de-identified data to the University of Bern, Switzer-
land, for cleaning and analysis.
2.2 | Inclusion criteria and definitions
All patients living with HIV aged <16 years at cART start (irre-
spective of likely mode of infection) were included in descrip-
tive analyses if they had documented sex and cART start date
after 1994, were treatment-na€ıve at cohort entry (except for
exposure to antiretrovirals for prevention of mother-to-child
transmission (PMTCT)) or had CD4 measured at first cART
start if not na€ıve at cohort entry. For further analyses, we
excluded data from low- or middle-income countries before
widespread cART rollout began in 2002 and from countries
that contributed <50 patients with a CD4 measurement at
cART start. We also excluded data on children who started
therapy in a year and country for which <10 children with
CD4 measures were reported as well as data from the last cal-
endar year in countries where no CD4 measures were avail-
able after May of that calendar year. cART was typically
defined by participating cohorts as a regimen of ≥3 antiretrovi-
ral drugs from ≥2 drug classes. The baseline CD4 value was
defined as the value nearest the cART start date within 6 to
+1 months of start. Countries were grouped according to the
World Bank classification of annual Gross National Income per
capita 2013 as low-income (LIC, ≤US$1045), lower middle-
income (LMIC, US$1046-4125), upper middle-income (UMIC,
US$4126 to 12,745) and high-income (HIC, ≥US$12,746). We
used the 2013 classification as this was the most recent year
for which data was included [28]. Age groups at cART initiation
were less than twelve months, twelve to thirty-five months,
thirty-six to fifty-nine months, five to eleven years and twelve
to fifteen years. Severe immunodeficiency was defined accord-
ing to WHO as CD4% <25% (age <12 months), <20% (12 to
35 months), <15% (36 to 59 months) and CD4 count <200
cells/lL or CD4% <15% (≥5 years) [29].
2.3 | Multiple imputation of missing CD4
measurements
We imputed missing CD4 measures at cART initiation from
1996 (HIC) and 2002 (LIC, LMIC and UMIC) onwards for
countries and calendar years. We imputed the arcsine square
root of CD4% and square root of CD4 cell count simultane-
ously using chained equations and predictive mean matching,
adjusting for country and year of cART start, stratifying by
sex, age, income group and cohort. We generated 50 imputed
data sets and combined these using Rubin’s rule [30].
2.4 | Analysis of temporal trends in CD4
measurements
We used generalized additive mixed models to analyse tempo-
ral trends in CD4 measures by sex, age and country income
group. We assessed three key outcomes at cART initiation:
the proportion of children with severe immunodeficiency;
median CD4% (aged <5 years); and median CD4 count (aged
≥5 years). Sex, age group and income group and their interac-
tions were entered as fixed effects and country as a random
intercept. Yearly trends were smoothed by sex, age group and
income group. Data were aggregated by calendar year (three
to sixteen years, depending on country), country (thirty-two
countries), sex and age group prior to analysis: each combina-
tion of these factors corresponded to a cell in the analysis.
For each cell, we calculated the number of children with sev-
ere immunodeficiency and the median CD4% and count. Each
cell was entered in the model with a two-part weight. The first
part incorporated the precision of the aggregated values for
each cell into the model and corresponded to the number of
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observations contained in a cell, divided by the average num-
ber of observations in all cells in the same income group. The
second part corresponded to the ratio of the number of
patients that were newly enrolled in that cohort for that year
and the number of patients that started cART in that country
during that year [31]. The weights of the second part were
also normalized by country income group. We used the data
set with imputed data for the main analysis. In sensitivity anal-
yses, we fitted the model restricted to the subset with com-
plete data.
2.5 | Influence of WHO guidelines on the
proportion starting cART with advanced disease
From 2002 to 2013, there were two major changes in WHO
paediatric cART initiation guidelines. Before 2006, WHO
guidelines for initiation of cART in children were included in
the adult guidelines; children were cART eligible with WHO
Stage 3 disease (AIDS; note Stage 4 disease not defined at
that time) or Stage 2 disease if CD4% <20% (age
<18 months) or <15% (age >18 months) [32]. In 2006, WHO
released revised stand-alone guidelines for children, based on
a public health approach [1]. In the 2006 guidelines, WHO
cART eligibility criteria were: WHO Clinical Stages 3/4,
CD4 < 1500 cells/lL or 25% (age <12 months), CD4 < 750
cells/lL or 20% (12 to 35 months), CD4 < 350 cells/lL or
15% (36 to 59 months) and CD4 ≤ 200 cells/lL (≥5 years)
[1]. In 2010, WHO recommended cART regardless of immuno-
logic or clinical thresholds for children <2 years, children with
WHO Clinical Stages 3/4, CD4 < 750 cells/lL or 25% (age
two to five years) and CD4 ≤ 350 cells/lL (age ≥5 years) [2].
We performed segmented (piecewise) linear regression to test
whether the guideline changes affected the speed of decline
in the proportion of children with severe immunodeficiency at
cART initiation. Segments were calendar periods 2002 to
2005, 2006 to 2009 and 2010 to 2013, assuming change
points at 2006 and 2010 [1,2]. We used a generalized linear
mixed effects model with income groups as fixed effects and
countries as random effects. The main slope was the middle
period (2006 to 2009). The variability in the country effect
was expressed by a different intercept, allowing parallel devia-
tions from the average income group and random slopes,
accounting for slower or faster than average decreases. The
model allowed different slopes for different periods but forced
the line segments for the three periods to be continuous at
the change points, and the change in slopes between periods
to be the same for all countries within each income group. We
estimated confidence intervals (CI) to determine whether
slopes in 2002 to 2005 and 2010 to 2013 differed from the
reference slope (2006 to 2009).
The technical appendix provides further details on the mul-
tiple imputation and smoothing (see Appendix 1). Analyses
were conducted in R 3.1.0 (R Core Team, Vienna, Austria).
3 | RESULTS
3.1 | Descriptive analyses
Data from 67,486 children from 44 countries <16 years old
at cART start were submitted to the data centre (Figure S1).
We excluded 13,383 participants who did not meet the
inclusion criteria, mostly because they were not treatment-
na€ıve at cohort entry; hence, 54,103 children from 41 coun-
tries were included in descriptive analyses (Figure 1). We
excluded 1950 children from further analyses using multiple
imputation (nine countries) either because their CD4 mea-
sures were before 1996 (HIC) or 2002 (LIC, LMIC and
UMIC) (268 children), or from calendar years with <10 chil-
dren in that country with CD4 measures (1544 children) or
with no measure after May of the last calendar year for
the relevant country (138 children) (Figure S1). Data typi-
cally spanned the years 2003 to 2013 in low- and middle-
income countries and 1997 to 2012 in HIC; in the USA,
data were only available for 1996 to 2006, as all partici-
pants initiated cART before 2007 (Table 1). The median
year of cART initiation ranged from 1998 in the US to
2012 in Mozambique. The median (interquartile range
(IQR)) age of children starting cART was 6 years (3 to 10)
in LIC, 5 (2 to 10) in LMIC, 6 (2 to 10) in UMIC and 6 (2
to 10) in HIC. Median CD4 cell counts/percentages at
cART initiation by country and sex are shown in Table 2.
The median CD4 count at cART start for children ≥5 years
old was 250 cells/lL (106 to 416) in LIC, 258 (118 to
446) (LMIC), 189 (57 to 349) (UMIC) and 348 (179 to
601) (HIC). Similar patterns were evident for CD4% in chil-
dren <5 years (Table 2). The overall percentage (95%CI) of
children starting cART with severe immunodeficiency was
48% (47% to 49%) (LIC), 52% (51% to 53%) (LMIC), 57%
(56% to 58%) (UMIC) and 31% (30% to 33%) (HIC).
3.2 | Analysis of temporal trends in CD4
measurements
Further analyses were based on 52,153 children, among
whom CD4 measurements were imputed for 17,790 patients.
(Table S1). Figure 2 shows modelled temporal trends in the
prevalence of severe immunodeficiency at cART initiation. Fig-
ure 3 shows corresponding trends in median CD4 counts
(children aged ≥5 years) or CD4% (children <5 years). In LIC,
the estimated percentage of children starting cART with sev-
ere immunodeficiency declined from 70% in 2004 to 42% in
2013. Corresponding figures were 67% to 46% (LMIC), 61%
to 43% (UMIC) and 45% to 14% (HIC, 1996 to 2012). Of
note, in LIC among children aged <1 year, there was almost
no decline in the proportion starting cART with severe immun-
odeficiency.
In LIC, the median CD4 cell count at cART initiation in chil-
dren aged ≥5 years increased by 67% during 2004 to 2013,
(162 to 271 cells/lL). Corresponding increases were 55%
(151 to 234 cells/lL) (LMIC), 35% (164 to 222 cells/lL)
(UMIC) and 144% (185 to 452 cells/lL) (HIC, 1996 to 2012).
In children aged <5 years, median CD4% increased during
2004 to 2013 from 11% to 17% in LIC, 10% to 16% in LMIC,
14% to 20% in UMIC and 22% to 29% in HIC (1996 to
2012) (Figure 3). Results of complete case analysis were simi-
lar (Figures S2 and S3).
Temporal trends in median age at cART initiation varied
among country income groups (Figure S4). There was no clear
trend in median age at cART initiation in LMIC, while there
was a decrease from 2004 to 2013 in LIC (6.2 to 4.6 years)
and an increase in UMIC (4.5 to 7.8 years) as well as HIC
(2.1 (1996) to 7.4 years (2012)).
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Table 1. Characteristics at cART initiation of 54,103 children starting cART by country income group.
Country
Number of
patients Median age in years
Median calendar year
of starting cART
Calendar year
range of data
Calendar
year range of
data used in
analysisFemale Male Female Male Female Male
Low-income
Benin 103 120 4 4 2008 2009 2002 to 2012 2004 to 2011
Burkina Faso 196 176 7 6 2008 2009 2001 to 2012 2003 to 2012
Cambodia 191 196 6 6 2007 2007 2004 to 2012 2005 to 2010
Congo, DR 529 524 6 6 2009 2009 2004 to 2013 2004 to 2013
Haiti 373 314 6 7 2009 2008 2003 to 2013 2003 to 2012
Kenya 4227 4199 6 6 2010 2010 2002 to 2012 2003 to 2012
Malawi 2113 2072 6 6 2009 2009 2000 to 2013 2005 to 2010
Mali 465 659 4 4 2007 2007 2001 to 2012 2002 to 2012
Mozambique 217 224 2 2 2012 2012 2005 to 2014 2007 to 2013
Rwanda 506 497 9 8 2008 2008 2000 to 2013 2004 to 2013
Tanzania, UR 398 378 7 6 2009 2009 2005 to 2013 2005 to 2012
Togo 155 154 4 4 2011 2011 2005 to 2012 2010 to 2012
Uganda 239 252 4 5 2010 2010 2002 to 2012 2006 to 2011
Zimbabwe 1535 1537 9 9 2011 2011 1999 to 2014 2005 to 2013
Overall (IQR) 11,247 11,302 6
(3 to 11)
6
(3 to 10)
2010
(2007 to 2011)
2009
(2007 to 2011)
1999 to 2014 2002 to 2013
Lower middle-income
Cameroon 4 1 12 15 2006 2007 2003 to 2008 Excluded
Cote d’Ivoire 973 1030 6 6 2007 2007 2001 to 2012 2004 to 2012
Ghana 249 276 6 5 2008 2009 2001 to 2012 2004 to 2012
Honduras 16 13 3 5 2005 2005 2002 to 2009 Excluded
India 49 68 9 8 2008 2008 2001 to 2012 2005 to 2010
Indonesia 103 111 3 2 2009 2008 2005 to 2013 2005 to 2012
Lesotho 355 381 6 6 2011 2010 2003 to 2014 2006 to 2013
Senegal 150 196 6 5 2009 2008 2000 to 2012 2005 to 2011
Vietnam 493 621 4 4 2009 2009 2005 to 2013 2005 to 2012
Zambia 7315 7090 6 5 2009 2009 2003 to 2011 2004 to 2011
Overall (IQR) 9707 9787 6
(2 to 10)
5
(2 to 9)
2009
(2007 to 2010)
2009
(2007 to 2010)
2000 to 2014 2004 to 2013
Upper middle-income
Argentina 5 5 7 6 2002 2009 2001 to 2010 Excluded
Brazil 212 200 4 5 2003 2003 1997 to 2012 2002 to 2012
Malaysia 119 130 5 4 2008 2008 2001 to 2013 2003 to 2011
Mexico 1 1 11 3 2007 1999 1998 to 2006 Excluded
Peru 54 44 6 3 2006 2006 2002 to 2014 2004 to 2007
South Africa 3328 3207 5 5 2009 2009 2000 to 2013 2002 to 2013
Thailand 686 595 8 8 2006 2006 2000 to 2013 2002 to 2012
Overall (IQR) 4405 4182 6
(2 to 10)
6
(2 to 9)
2009
(2006 to 2011)
2009
(2006 to 2011)
1997 to 2014 2002 to 2013
High-income
Australia 1 0 11 - 2000 - 1999 to 1999 Excluded
Austria 1 0 16 - 2001 - 2001 to 2001 Excluded
Denmark 31 17 8 7 2003 2003 1997 to 2012 Excluded
France 115 92 1 1 2005 2004 1996 to 2013 1997 to 2008
Germany 11 22 6 9 2004 2005 1998 to 2011 Excluded
Netherlands 114 115 3 4 2004 2004 1997 to 2013 1997 to 2012
Spain 181 159 2 2 2005 2005 1996 to 2013 1998 to 2011
Switzerland 1 0 16 - 1999 - 1999 to 1999 Excluded
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3.3 | Influence of WHO guidelines on the
proportion starting cART with advanced disease
There was a significant decrease in the percentage of children
starting cART with severe immunodeficiency in at least one
period in all country income groups (Table 3A, Table S2A).
The annual decrease in the proportion of children with severe
immunodeficiency at cART initiation between 2006 and 2009
was 3.0% (95% CI: 4.1 to 1.9%) (LIC), 2.1% (95% CI:
3.3 to 0.7%) (LMIC) and 2.7% (95% CI: 4.5 to 0.7%)
(UMIC). The slope coefficients from the segmented regression
model show that there was an acceleration in the rate of
decrease during the period 2006 to 2009 in LIC, LMIC and
UMIC, but no further significant change in the rate of
decrease from 2010 to 2013 (Table 3B, Table S2B).
4 | DISCUSSION
In our study of about 52,000 children from 32 countries, we
found that since the 2006 and 2010 WHO Guidelines
addressing paediatric cART eligibility, there have been annual
reductions in the proportion of children starting cART with
severe immunodeficiency in almost all country income groups.
By 2013, less than half of children had severe immunodefi-
ciency when starting cART in all country income groups. Nev-
ertheless, considerable global inequity in advanced HIV
disease at cART initiation remains; in 2013, >40% of children
in low- and middle-income countries still started cART with
severe immunodeficiency compared to <20% in HIC.
4.1 | Relationship with WHO Treatment Guidelines
The goal of increasing paediatric cART coverage is one of the
key reasons for the WHO 2015 recommendation of immedi-
ate cART irrespective of CD4 for all children [4]. It is there-
fore encouraging that previous guideline revisions that
expanded paediatric cART eligibility have been temporally
associated with reduction in the proportion of children with
advanced HIV disease at cART initiation. Nevertheless, except
in HIC, more than 40% of children continued to start cART
with severe immunodeficiency in 2013. This supports expand-
ing immediate cART to all children, and indicates that WHO
guideline changes alone are insufficient to achieve optimal
treatment coverage. Ongoing and proactive engagement by
WHO with ministries of health should focus on implementing
paediatric testing and treatment guidelines.
Expansion of cART eligibility needs to be accompanied by
efforts to ensure sufficient and sustainable access to HIV
commodities as well as strengthened health systems, including
trained health workers and infrastructure, which requires
political will and adequate funding [33]. Inequities in the pro-
portions of children starting cART with severe immunodefi-
ciency were not only seen between different country income
groups, but also among countries in the same income group.
For example, in LICs, the proportion of children starting cART
with severe immunodeficiency ranged across countries from
33% to 69%. This may be partly due to the particular pro-
grammes in these countries that contributed to this analysis,
and the years in which those programmes initiated the major-
ity of children on cART. It is also possible that different levels
of donor and national government funding and political will
contributed to these differences.
It is somewhat surprising that there were no clear
decreases in median age at cART start across all country
income groups since eligibility for immediate cART irrespec-
tive of CD4 values applied initially to the youngest children
(<2 years) and only expanded to those <5 years in 2013
(Figure S4) [2,3]. However, interpreting trends in age at
cART initiation is complex [21]. The WHO guideline shifts
towards universal treatment eligibility for progressively older
groups of children have been accompanied by recommenda-
tions of more effective PMTCT, namely universal lifelong
cART for all pregnant and breastfeeding women (so-called
“Option B+”). By 2013, the population of two- to five-year
olds eligible for immediate treatment would likely have
decreased, both due to fewer new infections as well as
some children already having started cART at less than two
years of age following the implementation of 2010 guide-
lines. The median age at cART initiation thus depends on
the effectiveness of PMTCT programmes in preventing new
infant infections, capacity for EID and early cART, as well
as the backlog of older children not yet on therapy [34,35].
There was a decrease in age at cART initiation in LIC, sug-
gesting that the WHO 2010 guideline recommendation of
universal cART for all children <2 years may have had the
greatest impact in the poorest countries, where EID
capacity increased substantially in this period [36-39]. Nev-
ertheless, there was little temporal improvement in the pro-
portion of children <1 year with severe immunosuppression,
Table 1. (Continued)
Country
Number of
patients Median age in years
Median calendar year
of starting cART
Calendar year
range of data
Calendar
year range of
data used in
analysisFemale Male Female Male Female Male
United Kingdom 601 590 7 6 2005 2004 1996 to 2013 1997 to 2012
United States 741 681 7 6 1998 1998 1995 to 2010 1996 to 2006
Overall (IQR) 1797 1676 6
(2 to 10)
6
(2 to 10)
2002
(1998 to 2006)
2001
(1998 to 2006)
1995 to 2013 1996 to 2012
cART, combination antiretroviral therapy; IQR, interquartile range.
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indicating that further improvements in EID and early cART
access are urgently needed.
While there was an increase in overall age at cART initiation
in UMIC, this may partly be due to effectiveness of PMTCT
programmes preventing new infections. These countries nev-
ertheless experienced the steepest decline in the proportion
of infants with severe immunosuppression, indicating substan-
tial progress in achieving cART initiation before the onset of
advanced disease in infants. The overall increase in median
age in both UMIC and HIC is likely due to reductions in new
infant infections due to effective PMTCT, with a relative
increase in the proportion of long-term survivors initiating
cART. Indeed, in Southern Africa, we have shown an increase
in the proportions of children <1 year and >10 years old initi-
ating cART [40]. In Europe, many older patients presenting for
testing and care may be immigrants, predominantly from sub-
Saharan Africa [41-43].
4.2 | From improving paediatric cART access to
improving paediatric HIV outcomes
CD4 at cART initiation is a useful indicator of responsiveness
to WHO treatment initiation guidelines and indicates the
extent to which we are successfully preventing advanced HIV
disease through early cART initiation [44]. Early cART initia-
tion and retention are particularly critical in infants, as disease
progression without cART is rapid and associated with high
mortality. However, increasing CD4 at treatment start will
only result in improved paediatric outcomes if those children
are retained and adherent to effective treatment. There is a
much-needed emphasis on children in the UNAIDS 90:90:90
goals which focus not just on diagnosis and treatment access,
but also aim for 90% retention on cART, with 90% viral sup-
pression [44]. Indeed, the WHO 2015 treatment guidelines
highlight as a research gap the effect of early cART on reten-
tion and adherence [4]. The IeDEA collaboration has previ-
ously found loss-to-follow-up rates in children by 18 months
after cART initiation ranging from 4.1% in Asia to 21.8% in
West Africa [45]. A recent analysis as part of an IeDEA-WHO
Collaboration found that children <2 years of age and youth
aged 15 to 24 years were least likely to be retained in care
[46]. Expanding paediatric cART therefore requires strategies
not only to improve diagnosis and cART initiation, but also to
optimize retention and support adherence across the paedi-
atric and adolescent age spectrum. As more children are initi-
ated on treatment at younger ages, better access to viral load
monitoring to assess treatment effectiveness as well as paedi-
atric-friendly second- and third-line drugs will become more
important.
4.3 | Strengths and limitations
This analysis included a large number of children from many
countries and all income group settings. It is one of the first
analyses with substantial numbers of children that initiated
cART after the WHO 2010 guidelines, allowing enough time
to examine their effects. The inclusion of European data
where, at least in some countries, there were sufficient num-
bers of children initiating cART to include data up to 2012,
allows for comparison between all income settings after the
2006 and 2010 guideline revisions. A key limitation of our
study is that we looked at the impact of WHO guidelines and
not individual country guidelines on changes in CD4 at cART
initiation. Although in some cases country guidelines pre-date
WHO guidelines, they more frequently lag behind WHO
guidelines, which may explain the lack of a clearer effect of
WHO guidelines on CD4 at cART start. Furthermore, in some
country income groups, most data were from only one or two
Figure 1. Map of countries contributing patients to the collaborative analysis.
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countries. Similarly, for some countries, data may have origi-
nated from a small number of programmes or from particular
years. This may partly explain the diversity in findings within
the same country income group, and our results may not be
generalizable to the whole country or income group. However,
to reflect reality as best as possible, we used a weighted
analysis approach, with more weight assigned not only to
more precise estimates obtained from countries contributing
many observations to our data set but also dependent on the
UNAIDS estimated number of children starting cART in a
given country and year [31], so that countries with many chil-
dren starting cART were adequately represented in our
Figure 2. Severe immunodeficiency at the start of cART by age, sex and country income groups (colours).
Severe immunodeficiency was defined according to WHO as CD4% <25% (age <12 months), <20% (12 to 35 months), <15% (36 to 59 months)
and CD4 count <200 cells/lL or CD4% <15% (≥5 years). Results from generalized additive mixed effects models based on 52,153 children after
imputation of missing data. 95% CIs are shown as shaded areas. Vertical lines indicate the changes in WHO guidelines on when to start cART.
Age groups are shown along the right edge. Note that no data available for the analysis for 2003 in LMIC and after 2012 for HIC; hence, the
periods shown on the graph differ slightly by country income group. cART, combination antiretroviral therapy; WHO, World Health Organization;
LMIC, lower middle-income country; HIC, high-income country.
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analysis. It is also possible that the facilities included in our
analysis reflect better access to paediatric cART than occurs
in the whole country or income group. However, almost all
sites from LMICs in our cohorts are routine care facilities
rather than dedicated research cohorts, and followed the rele-
vant national cART guidelines. The routine nature of the data
Figure 3. Median CD4 cell count in children aged 5 years or older and median CD4% in children below 5 years of age at the start of cART
by age, sex and income group (colours).
Results from generalized additive mixed effects models based on 52,153 children after imputation of missing data. 95% CIs are shown as shaded
areas. Vertical lines indicate the changes in WHO guidelines on when to start cART. Age groups are shown along the right edge. cART, combina-
tion antiretroviral therapy; WHO, World Health Organization.
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is reflected in the substantial proportions of missing CD4 data
at cART initiation, with almost one third of patients missing a
CD4 measurement in LIC. We conducted multiple imputation
to minimize bias due to missing data. Results including the
imputed values were very similar to those of complete case
analyses. However, it is possible that there is residual bias.
For example if children with poorer health were less likely to
have CD4 measurements performed, this would violate the
assumption of values “missing at random” [30] and lead to an
underestimation of the proportion of children starting cART
with severe immunodeficiency.
5 | CONCLUSIONS
The results of this study represent a milestone in efforts to
increase paediatric cART access worldwide. We are almost half-
way there. In 2012/2013, for the first time in all country income
groups, approximately half of children initiating cART did not
have severe immunodeficiency. This is at least partly attributable
to WHO guidelines changes that expanded paediatric cART eligi-
bility. Nevertheless, the persistence of disparities in cART access
across income group settings are also reflected in our data show-
ing that in 2013 there were still >40% of children starting cART
with severe immunosuppression in LMICs. The WHO 2016
guidelines provide an opportunity to expand paediatric cART
access to infants, children and adolescents and encourage moni-
toring of the effect of the guidelines not only on immunological
status at cART initiation, but also on retention and treatment
effectiveness to comprehensively evaluate the effectiveness of
paediatric cART programmes.
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Table S2. Decline in percentage of children starting cART with
severe immunodeficiency by calendar period, reflected by (A)
average change in percentage per year within each WHO
guideline period and (B) rate of decrease presented as esti-
mated slope coefficient from the segmented regression analysis.
This analysis was based on complete cases (34,363 children)
Figure S1. Flow chart of children included and excluded from
analyses.
Figure S2. Severe immunodeficiency at the start of cART by
age (rows), sex (columns) and country income groups (colours).
Results from generalized additive mixed effects models based
on 34,363 children with complete data. 95% CIs are shown as
shaded areas.
Figure S3. Median CD4 cell count in children aged 5 years or
older and median CD4% in children below 5 years of age at
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